Antimelancholic medicine prepared with jujube camp materials

ABSTRACT

An antimelancholic pharmaceutical composition or health products prepared with jujuba cAMP materials and a preparative method are provided in the present invention. The present pharmaceutical composition includes jujuba cAMP as a solo effective ingredient for treating the depression. The present method for preparing the jujuba cAMP includes chromatographing a jujuba extract with a macroporous resin bound with an aldehyde group.

CROSS-REFERENCE TO RELATED APPLICATION AND CLAIM OF PRIORITY

The application claims the benefit of PCT Patent Application No.PCT/CN07/03397, filed on Nov. 30, 2007, in the State IntellectualProperty Office of the P.R.C., the disclosures of which are incorporatedherein in their entirety by reference.

FIELD OF THE INVENTION

The present invention relates to a medicine or a healthcare productprepared from jujuba cyclic adenosine monophosphate (jujuba cAMP)material for treating depression (melancholia). Furthermore, the presentinvention relates to a preparation method of the medicine or thehealthcare product from the jujuba cAMP material for treatingdepression.

BACKGROUND OF THE INVENTION

Depression is a common disease. According to statistics, about 25%females in the global population bad been experiencing depression intheir lives, and about 10% males had been experiencing depression(referring to Modern Psychology written by Ch'un-Hsing Chang). WorldHealth Organization (WHO) published, “The incidence of depression in theworld is about 11%. At present, there are about 340 millionpsychological depressed patients in the world, and the number isincreasing. It is found in the investigation that depression willincrease to be the number two common disease in the world from now on to20 years later.”

At present, anti-depression pharmaceuticals consist mainly Prozac, Paxiland Zoloft, etc., which belong to selective serotonin reuptake inhibitor(SSRI), serotonin-norepinephrine reuptake inhibitor (SNRT), andnorepinephrine and dopamine reuptake inhibitor (NDRI), inhibiting theuptake of 5-hydroxytryptamine (5-HT), norepinephrine (NE) and dopamine(DA). The mechanism by which these pharmaceuticals function is byincreasing the amount of human neurotransmitters such as 5-HT so as todecrease and alleviate the symptoms of depression.

However, these pharmaceuticals have various side effects of differentseverities, such as increased suicide rate, headache, giddiness,vertigo, insomnolence, hypersomnia, tinnitus, thirsty, apocleisis,orexis, increased body weight, increased blood pressure, stomach upset,regurgitation nausea, emesis, dyspepsia, diarrhea, constipation, legpain, skin rash, dither, convulsions, hyperhidrosis, edema, sexualappetite, impotence, etc. In recent years, the depressionpharmaceuticals, such as Prozac, etc., had become a serious socialproblem. In 2004, the Food and Drug Administration (FDA) of the UnitedStates further mandated the pharmaceutical companies to revise productlabels to clearly state the side effects and cautions in theinstructions of 32 major anti-depression pharmaceuticals in the market,and emphasized to physicians and nurses that these pharmaceuticals mightincrease children's and adolescents' suicide rate. Among them, Paxil waseven found to be harmful in 1996, and has been recalled continually fromthe market since 2001. In June 2004, the New York State Attorney Generalaccused GlaxoSmithKline Company of the Great Britain of beguilinglyconcealing the research report of the linkage between Paxil and“increased risk of suicidal behavior and tendencies in adolescents.” Inlight of the current situation, the search for a new generation ofpharmaceuticals with fewer side effects and more pronounced/potentanti-depression qualities has become the center of attention of theentire pharmaceutical world.

It is therefore attempted by the applicant to deal with the abovesituation encountered in the prior art.

SUMMARY OF THE INVENTION

The purpose of the present invention is to provide a medicine or ahealthcare product prepared from material containing jujuba cAMP fortreating depression to overcome the insufficiency of the presenttechnology. In particular, the invention provides new technical schemesthat avoid the side effects of the present anti-depression medicine.

Another purpose of the present invention is to provide the preparationmethod of the medicine or the healthcare product from the materialcontaining jujuba cAMP for treating depression.

The resolving scheme of the pharmaceutical of the present invention isthe result of substantial efforts of the inventor. The resolving schemecombines the theories of modern medicine and pharmacology. Inparticular, the resolving scheme combines the research fields ofadenylate cyclase (AC)—cyclic adenosine monophosphate (cAMP) signalingtransduction pathway, the cAMP-inducing transcription process, and more.The inventor has been dedicated to the research of traditional botanicalmaterials for treating depression. After much animal experimentation,jujuba cAMP, being the extrinsic non-hydrolyzable cAMP, which is knownto the skilled person in the field, can participate in the cAMPmetastatic process of the organism, and simulate the enzyme function toincrease cAMP in the cells, and thus achieves the anti-depressioneffect. Jujuba cAMP is extracted from the daily edible fruit, jujuba.The cAMP isolated from a jujuba extraction is the proportion of cAMPoriginally present prior to extraction and which survived the isolationprocess because it was not hydrolyzed by the conditions applied duringthe isolation process. In the long history of human daily consumption ofjujuba as fruit and as Chinese herbal medicine materials, there has beenno case of a harmful reaction associated with taking jujuba, in contrastto the present anti-depression pharmaceuticals that have manyundesirable side effects. After the inventor extracted jujuba containinga trace amount of jujuba cAMP (about one in ten thousand) by water, theinventor further purified the jujuba water extract into the jujubaextract containing 1% of jujuba cAMP. The jujuba extract thus processedwas tested in the animal experiments for anti-experimental depressionfunction, and the results demonstrate that the jujuba extract has ananti-experimental depression function. In contrast, the jujuba waterextract that was not further purified to increase the concentration ofjujuba cAMP, while containing a trace amount of jujuba cAMP, did nothave an obvious anti-experimental depression function when the normalpharmaceutical dose was proceeded in the animal experiment testing forthe anti-experimental depression function. Therefore, the inventionsubmits the new technical scheme of manufacturing a pharmaceutical fromthe raw material of jujuba cAMP for treating depression, so as toimprove the insufficiency in the prior art.

Jujuba cAMP:

Source: the dried matured fruit of Zizyphus jujuba Mill.

Synonym: 3′,5′-cyclic adenosine monophosphate or 3′,5′-cyclic phosphate.

English name: cyclic adenosine-3′,5′-monophosphate.

Molecular formula and relative molecular weight: C₁₀H₁₃N₅O₆P.H₂O and347.23 respectively.

Biological activity: The activity of cAMP-like material in jujuba issimilar with that of cAMP. cAMP being the extrinsic non-hydrolyzablecAMP can simulate the enzyme function to increase cAMP in the cells.

Structural formula:

In accordance with one aspect of the present invention, a medicine fortreating depression is provided. The medicine includes jujuba cAMP.

Preferably, the medicine is manufactured as an oral medicine.

Preferably, the medicine has a dosage form being one selected from agroup consisting of a tablet, a capsule, a powder, a pill, a dust, asolution, a microcapsule, a suspension, an emulsion, a particle, adropping pill and a roll.

Preferably, the dosage form is a first oral dosage form for taking onceper day and has 0.003 mg to 0.3 mg of jujuba cAMP. Preferably, the firstoral dosage form has 0.01 mg to 0.25 mg of jujuba cAMP.

Preferably, the dosage form is a second oral dosage form for takingtwice per day and has 0.002 mg to 0.2 mg of jujuba cAMP. Preferably, thesecond oral dosage form has 0.005 mg to 0.12 mg of jujuba cAMP.

Preferably, the dosage form is a third oral dosage form for takingthrice per day and has 0.001 mg to 0.1 mg of jujuba cAMP. Preferably,the third oral dosage form has 0.003 mg to 0.08 mg of jujuba cAMP.

Preferably, the dosage form is a fourth oral dosage form for taking fourtimes per day and has 0.0008 mg to 0.06 mg of jujuba cAMP. Preferably,the fourth oral dosage form has 0.002 mg to 0.04 mg of jujuba cAMP.

Preferably, the medicine according to claim 1 further includes at leastone of a pharmacologically acceptable carrier and an additive.

Preferably, the medicine is manufactured as a healthcare product or anutrient supplement.

Preferably, jujuba cAMP is extracted from jujuba.

Preferably, jujuba is extracted for obtaining a first extract having afirst jujuba cAMP concentration, the first extract is further extractedfor obtaining a second extract having a second jujuba cAMPconcentration, the second jujuba cAMP concentration is higher than thefirst jujuba cAMP concentration, and the second extract is a rawmaterial in the medicine.

In accordance with another aspect of the present invention, apreparation method of jujuba cAMP of a medicine for treating depressionis provided. The preparation method comprises steps of (a) extractingjujuba for obtaining a first extract having a first jujuba cAMPconcentration; and (b) purifying the first extract for obtaining asecond extract having a second jujuba cAMP concentration. The secondjujuba cAMP concentration is higher than the first jujuba cAMPconcentration.

Preferably, the step (b) is processed by chromatographing the firstextract with a macroporous resin bound with an aldehyde group.

Preferably, the step (b) further comprises steps of (b1)chromatographing the first extract with an OU-2 macroporous resin boundwith the aldehyde group; and (b2) chromatographing the first extractwith an ME-2 macroporous resin bound with the aldehyde group.

In accordance with another aspect of the present invention, a method forpreparing jujuba cAMP is provided. The method includes steps of (a)extracting jujuba for obtaining a first extract; and (b)chromatographing the first extract with a macroporous resin having analdehyde group bound thereon.

The above objectives and advantages of the present invention will becomemore readily apparent to those ordinarily skilled in the art afterreviewing the following detailed descriptions and accompanying drawings,in which:

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flowchart showing a preparation method of a medicine inaccordance with a first preferred embodiment of the present invention;

FIG. 2 is a flowchart showing a preparation method of a medicine inaccordance with a second preferred embodiment of the present invention;

FIG. 3 is a flowchart showing a preparation method of a medicine inaccordance with a third preferred embodiment of the present invention;

FIG. 4 is a flowchart showing a preparation method of a medicine inaccordance with a fourth preferred embodiment of the present invention;

FIG. 5 is a flowchart showing a preparation method of a medicine inaccordance with a fifth preferred embodiment of the present invention;

FIG. 6 is a flowchart showing a preparation method of a medicine inaccordance with a sixth preferred embodiment of the present invention;and

FIG. 7 is a flowchart showing a preparation method of a medicine inaccordance with a seventh preferred embodiment of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention will now be described more specifically withreference to the following embodiments. It is to be noted that thefollowing descriptions of preferred embodiments of this invention arepresented herein for purpose of illustration and description only; it isnot intended to be exhaustive or to be limited to the precise formdisclosed.

In order to accomplish the purpose of the present invention, thetechnical schemes of the present invention are particularly provided asfollows.

EXAMPLE 1

The oral medicine of the present invention for treating depression wasmanufactured from the material including jujuba cAMP.

EXAMPLE 2

The raw material including jujuba cAMP was manufactured as anypharmacologically common oral medicine dosage form of the presentinvention, such as tablet, capsule, powder, pill, dust, solution,microcapsule, suspension, emulsion, particle, dropping pill, roll, etc.,for treating depression.

EXAMPLE 3

The pharmaceutical of the present invention was manufactured from theraw material including 0.003˜0.3 mg of jujuba cAMP as a dosage form fortaking once per day. Preferably, the pharmaceutical of the presentinvention was manufactured from the raw material including 0.01˜0.25 mgof jujuba cAMP as a dosage form for taking once per day.

EXAMPLE 4

The pharmaceutical of the present invention was manufactured from theraw material including 0.002˜0.2 mg of jujuba cAMP as a dosage form fortaking twice per day. Preferably, the pharmaceutical of the presentinvention was manufactured from the raw material including 0.005˜0.12 mgof jujuba cAMP as a dosage form for taking twice per day.

EXAMPLE 5

The pharmaceutical of the present invention was manufactured from theraw material including 0.001˜0.1 mg of jujuba cAMP as a dosage form fortaking thrice per day. Preferably, the pharmaceutical of the presentinvention was manufactured from the raw material including 0.003˜0.08 mgof jujuba cAMP as a dosage form for taking thrice per day.

EXAMPLE 6

The pharmaceutical of the present invention was manufactured from theraw material including 0.0008˜0.06 mg of jujuba cAMP as a dosage formfor taking four times per day. Preferably, the pharmaceutical of thepresent invention was manufactured from the raw material including0.002˜0.04 mg of jujuba cAMP as a dosage form for taking four times perday.

EXAMPLE 7

After jujuba was fractured, the fractured jujuba was soaked in the waterat room temperature, and then the soaked jujuba underwent decoction andalcohol sedimentation for obtaining the jujuba extract, which wasfurther absorbed, sequentially separated by the OU-2 and ME-2macroporous resins and dried. Finally, the jujuba extract containinghigh concentration of jujuba cAMP was obtained to be the raw materialfor preparing the pharmaceutical of the present invention.

EXAMPLE 8

The oral medicine of the present invention can include thepharmacologically acceptable carriers, additives and the compositionthereof.

EXAMPLE 9

The oral medicine of the present invention can be further manufacturedas healthcare product and nutrient supplements.

In order to accomplish the purpose of the present invention, thepreparation methods of the pharmaceutical is provided as follows.

Method 1:

In accordance with the pharmaceutical standard method of GoodManufacturing Practice (GMP), the oral medicine of the present inventionfor treating depression was manufactured from the raw material includingjujuba cAMP.

Method 2:

In accordance with the pharmaceutical standard method of GMP, the rawmaterial including jujuba cAMP was manufactured as any pharmacologicallycommon oral medicine dosage form of the present invention, such astablet, capsule, powder, pill, dust, solution, microcapsule, suspension,emulsion, particle, dropping pill, roll, etc., for treating depression.

Method 3:

In accordance with the pharmaceutical standard method of GMP, thepharmaceutical of the present invention was manufactured from the rawmaterial including 0.003˜0.3 mg of jujuba cAMP as a dosage form fortaking once per day. Preferably, the pharmaceutical of the presentinvention was manufactured from the raw material including 0.01˜0.25 mgof jujuba cAMP as a dosage form for taking once per day.

Method 4:

In accordance with the pharmaceutical standard method of GMP, thepharmaceutical of the present invention was manufactured from the rawmaterial including 0.002˜0.2 mg of jujuba cAMP as a dosage form fortaking twice per day. Preferably, the pharmaceutical of the presentinvention was manufactured from the raw material including 0.005˜0.12 mgof jujuba cAMP as a dosage form for taking twice per day.

Method 5:

In accordance with the pharmaceutical standard method of GMP, thepharmaceutical of the present invention was manufactured from the rawmaterial including 0.001 ˜0.1 mg of jujuba cAMP as a dosage form fortaking thrice per day. Preferably, the pharmaceutical of the presentinvention was manufactured from the raw material including 0.003˜0.08 mgof jujuba cAMP as a dosage form for taking thrice per day.

Method 6:

In accordance with the pharmaceutical standard method of GMP, thepharmaceutical of the present invention was manufactured from the rawmaterial including 0.0008˜0.06 mg of jujuba cAMP as a dosage form fortaking four times per day. Preferably, the pharmaceutical of the presentinvention was manufactured from the raw material including 0.002˜0.04 mgof jujuba cAMP as a dosage form for taking four times per day.

Method 7:

In accordance with the pharmaceutical standard method of GMP, afterjujuba was fractured, the fractured jujuba was soaked in the water atroom temperature, and then the soaked jujuba was extracted by decoctionand alcohol sedimentation for obtaining the jujuba extract, which wasfurther absorbed, sequentially separated by the OU-2 and ME-2macroporous resins and dried. Finally, the jujuba extract containinghigh concentration of jujuba cAMP was obtained to be the raw materialfor preparing the pharmaceutical of the present invention.

Method 8:

In accordance with the pharmaceutical standard method of GMP, the oralmedicine of the present invention can include the pharmacologicallyacceptable carriers, additives and the composition thereof.

Method 9:

In accordance with the pharmaceutical standard method of GMP, the oralmedicine of the present invention can be further manufactured ashealthcare product and nutrient supplements.

THE PREFERRED EMBODIMENT

The present invention is further illustrated as follows by combining thefigures and the preferred embodiments.

Embodiment 1

Please refer to FIG. 1, which is the flowchart showing a preparationmethod of a medicine in accordance with a first preferred embodiment ofthe present invention. In FIG. 1, in accordance with the pharmaceuticalstandard method of GMP, 30 g of the prepared jujuba extract having 1%jujuba cAMP was the raw material (step 101). Two hundred seventy (270) gof the adjuvant and the excipient (such as starch, lactose, silicondioxide and magnesium stearate, etc.) were added to manufacture thetablet dosage form (10,000 tablets, 30 mg/tablet and 0.03 mg jujuba cAMPper tablet) of the oral medicine or the healthcare product of thepresent invention for treating depression (steps 102 and 103).

Embodiment 2

Please refer to FIG. 2, which is the flowchart showing a preparationmethod of a medicine in accordance with a second preferred embodiment ofthe present invention. In FIG. 2, in accordance with the pharmaceuticalstandard method of GMP, 30 g of the prepared jujuba extract having 1%jujuba cAMP was the raw material (step 201). Four hundred twenty (420) gof the adjuvant and the excipient (such as starch, lactose, silicondioxide and magnesium stearate, etc.) were added to manufacture thetablet dosage form (15,000 tablets, 30 mg/tablet and 0.02 mg jujuba cAMPper tablet) of the oral medicine or the healthcare product of thepresent invention for treating depression (steps 202 and 203).

Embodiment 3

Please refer to FIG. 3, which is the flowchart showing a preparationmethod of a medicine in accordance with a third preferred embodiment ofthe present invention. In FIG. 3, in accordance with the pharmaceuticalstandard method of GMP, 50 g of the prepared jujuba extract having 1%jujuba cAMP was the raw material (step 301). Two hundred fifty (250) gof the adjuvant and the excipient (such as starch, lactose, silicondioxide and magnesium stearate, etc.) were added to manufacture thetablet dosage form (10,000 tablets, 30 mg/tablet and 0.05 mg jujuba cAMPper tablet) of the oral medicine or the healthcare product of thepresent invention for treating depression (steps 302 and 303).

Embodiment 4

Please refer to FIG. 4, which is the flowchart showing a preparationmethod of a medicine in accordance with a fourth preferred embodiment ofthe present invention. In FIG. 4, in accordance with the pharmaceuticalstandard method of GMP, 30 g of the prepared jujuba extract having 1%jujuba cAMP was the raw material (step 401). Two hundred ten (210) g ofthe adjuvant and the excipient (such as starch, lactose, silicon dioxideand magnesium stearate, etc.) were added to manufacture the tabletdosage form (12,000 tablets, 20 mg/tablet and 0.25 mg jujuba cAMP pertablet) of the oral medicine or the health food of the present inventionfor treating depression (steps 402 and 403).

Embodiment 5

Please refer to FIG. 5, which is the flowchart showing a preparationmethod of a medicine in accordance with a fifth preferred embodiment ofthe present invention. In FIG. 5, in accordance with the pharmaceuticalstandard method of GMP, 17 g of the prepared jujuba extract having 1%jujuba cAMP was the raw material (step 501). One hundred eighty three(183) g of the adjuvant and the excipient (such as starch, lactose,silicon dioxide and magnesium stearate, etc.) were added to manufacturethe tablet dosage form (10,000 tablets, 20 mg/tablet and 0.17 mg jujubacAMP per tablet) of the oral medicine or the healthcare product of thepresent invention for treating depression (steps 502 and 503).

Embodiment 6

Please refer to FIG. 6, which is the flowchart showing a preparationmethod of a medicine in accordance with a sixth preferred embodiment ofthe present invention. In FIG. 6, in accordance with the pharmaceuticalstandard method of GMP, 13 g of the prepared jujuba extract having 1%jujuba cAMP was the raw material (step 601). One hundred eighty seven(187) g of the adjuvant and the excipient (such as starch, lactose,silicon dioxide and magnesium stearate, etc.) were added to manufacturethe tablet dosage form (10,000 tablets, 20 mg/tablet, and 0.013 mgjujuba cAMP per tablet) of the oral medicine or the healthcare productof the present invention for treating depression (steps 602 and 603).

Embodiment 7

Please refer to FIG. 7, which is the flowchart showing a preparationmethod of a medicine in accordance with a seventh preferred embodimentof the present invention. In FIG. 7, in accordance with thepharmaceutical standard method of GMP, after 10 kg jujuba (step 701) wasfractured, the fractured jujuba was soaked in the water at roomtemperature, and then the soaked jujuba was extracted by decoction andalcohol sedimentation for obtaining the jujuba extract, which wasfurther absorbed, sequentially separated by the OU-2 and ME-2macroporous resins and dried, so as to obtain 30 g of the jujuba extracthaving jujuba cAMP (step 702). The jujuba extract having 1% (300 mg)jujuba cAMP was measured by high performance liquid chromatography(HPLC), so as to manufacture the oral medicine or the healthcare productof the present invention for treating depression (step 703).

Experiment 1: The Influence of Embodiment 3 in the Mouse Tail-HangingExperiment

1.1 Experimental animals: ICR mice, male, 22.0±2 g of body weight,secondary, were provided by the Experimental Animal Science Departmentof Capital Medical University, Beijing.

1.2 Experiment pharmaceuticals: The pharmaceutical of Embodiment 3 wasprovided by Beijing Wonner Biotech. Ltd. Co., and Paroxetine (Paxil) wasthe product of Zhong Mei Tianjin Smith Kline pharmaceuticals Co. Ltd.

1.3 Experimental equipment: Stop watch.

1.4 Dose designs: 1. High dose of Embodiment 3 (5 mg/kg/d); 2. middledose of Embodiment 3 (2.5 mg/kg/d); and 3. low dose of Embodiment 3(1.25 mg/kg/d).

1.5 Experimental method and result:

1.5.1 Group division and administration of drug: The mice were groupedrandomly, with 10 mice per group. 1. High dose of Embodiment 3 (5 mg/kg,per oral (P.O.), administered for 7 days); 2. middle dose of Embodiment3 (2.5 mg/kg, P.O., administered for 7 days); 3. low dose of Embodiment3 (1.25 mg/kg, P.O., administered for 7 days); 4. Paroxetine (3 mg/kg,P.O., administered for 7 days); and 5. physiological saline (P.O.).After 1 hour of the last drug administration, the mouse tail-hangingexperiment was proceeded.

1.5.2 Experimental method: The mouse's tail (1 cm to the tail end) wastaped on the wood strip higher than the platform for 5 cm and hung upfor 6 minutes. The time of non-movement of the mouse for the last 5minutes was recorded.

1.5.3 Statistic calculation: The experimental data are represented asX±SD , and the experimental result was calculated as analysis ofvariance (ANOVA) by SPSS 11.5 statistic software.

1.5.4 Experimental result: Please refer to Table 1.

TABLE 1 The influence of Embodiment 3 on the time of non-movement of themouse Animal Group number Time of non-movement (s) Physiological saline(control) 10 122.18 ± 45.78   Paroxetine 10 67.59 ± 39.09** High dose ofEmbodiment 3 10 75.13 ± 38.26** Middle dose of Embodiment 3 10 86.80 ±48.08*  Low dose of Embodiment 3 10 102.36 ± 13.68   In comparison withthe control group: *P < 0.05, and **P < 0.01.

Conclusion: According to the above experiment, it was found that thehigh and middle doses of Embodiment 3 of the present invention andParoxetine all decreased the time of non-movement after the mouse's tailwas hung. The differences were significant in comparison with thephysiological group (control). Therefore, the Embodiment 3 of thepresent invention having anti-experimental depression function can beextrapolated.

Experiment 2: The Influence of Embodiment 3 in the Mouse Swimming byCompulsion Experiment

2.1 Experimental animals: ICR mice, male, 22.0±2 g body weight,secondary, were provided by the Experimental Animal Science Departmentof Capital Medical University, Beijing.

2.2 Experiment pharmaceuticals: The pharmaceutical of Embodiment 3 wasprovided by Beijing Wonner Biotech. Ltd. Co., and Paroxetine (Paxil) wasthe product of Zhong Mei Tianjin Smith Kline pharmaceuticals Co. Ltd.

2.3 Experimental equipments: Stop watch.

2.4 Dose designs: 1. High dose of Embodiment 3 (5 mg/kg/d); 2. middledose of Embodiment 3 (2.5 mg/kg/d); and 3. low dose of Embodiment 3(1.25 mg/kg/d).

2.5 Experimental method and result:

2.5.1 Group division and administration of drug: The mice were groupedrandomly, with 10 mice per group. 1. High dose of Embodiment 3 (5 mg/kg,P.O., administered for 7 days); 2. middle dose of Embodiment 3 (2.5mg/kg, P.O., administered for 7 days); 3. low dose of Embodiment 3 (1.25mg/kg, P.O., administered for 7 days); 4. Paroxetine (3 mg/kg, P.O.,administered for 7 days); and 5. physiological saline (P.O.).

2.5.2 Experimental method: After 1 hour of the last administration ofdrug, the mouse was placed in 25° C. water in the glass tank having 10cm of the water depth and 14 cm of diameter. The accumulative time ofnon-movement of the mouse in the water for the last 5 minutes wasrecorded.

2.5.3 Statistic calculation: The experimental data are represented asX±SD, and the experimental result was calculated as ANOVA by SPSS 11.5statistic software.

2.5.4 Experimental result: Please refer to Table 2.

TABLE 2 The result of time of non-movement in the mouse swimming bycompulsion experiment Animal Group number Decreased temperature (° C.)Physiological saline (control) 10 127.53 ± 41.80  Paroxetine 10  83.42 ±40.71* High dose of Embodiment 3 10  80.39 ± 40.89* Middle dose ofEmbodiment 3 10 87.60 ± 43.42 Low dose of Embodiment 3 10 91.05 ± 47.21In comparison with the control group: *P < 0.05, and **P < 0.01.

Conclusion: According to the above experiment, it was found that thehigh doses of Embodiment 3 of the present invention and Paroxetine alldecreased the time of non-movement in the mouse swimming by compulsiontest. Therefore, the Embodiment 3 of the present invention havinganti-experimental depression function can be extrapolated.

Industrial Usefulness:

The application scopes of the oral medicine of the present invention fortreating depression lie in that:

1. the oral medicine described in the present invention for treatingdepression can include the pharmacologically acceptable additives;

2. the oral medicine described in the present invention for treatingdepression can be manufactured as the known dosage forms, such aspowder, capsule, and tablet, etc.; and

3. the oral medicine described in the present invention for treatingdepression can be manufactured as the health food for treatingdepression.

While the invention has been described in terms of what is presentlyconsidered to be the most practical and preferred Embodiments, it is tobe understood that the invention needs not be limited to the disclosedEmbodiments. On the contrary, it is intended to cover variousmodifications and similar arrangements included within the spirit andscope of the appended claims, which are to be accorded with the broadestinterpretation so as to encompass all such modifications and similarstructures.

What is claimed is:
 1. A method for extracting a cyclic adenosinemonophosphate (cAMP) from jujuba fruits, comprising steps of: (a)extracting an initially fractured jujuba fruit by a decoction process,wherein the fractured fruit is soaked in water and then thewater-soaked-fractured-fruit is contacted with alcohol to obtain a firstcAMP extract having a first cAMP concentration; and (b) chromatographingthe first cAMP extract with a macroporous resin absorbent with aldehydegroups covering its surface to obtain a second extract having a secondcAMP concentration, wherein the second cAMP concentration is higher thanthe first cAMP concentration.
 2. The preparation method according toclaim 1, further comprising the steps of: (b1) chromatographing thefirst extract with an OU-2 macroporous resin absorbent with the aldehydegroups covering its surface; and (b2) chromatographing the extractobtained from the step (b1) with an ME-2 macroporous resin absorbentwith the aldehyde groups covering its surface to obtain the secondextract.
 3. A method for extracting cyclic adenosine monophosphate(cAMP) from jujuba fruits, comprising steps of: (a) extracting aninitially fractured jujuba fruit by a decoction process, wherein thefractured fruit is soaked in water and then thewater-soaked-fractured-fruit is contacted with alcohol to obtain a firstcAMP extract; and (b) chromatographing the first cAMP extract with amacroporous resin absorbent with aldehyde groups covering its surface toobtain a chromatographed product having the cAMP.